PRL and neoplasm: Based on the linear regression analysis of the reduction in tumor maximum diameter and serum prolactin levels before and after BRC treatment (Figure 1A), patients were divided into two groups using the median percentage of tumor reduction as a cutoff: 25 relatively sensitive and 25 relatively insensitive patients.